Results 11 to 20 of about 92,765 (246)
HBsAg Loss as a Treatment Endpoint for Chronic HBV Infection: HBV Cure
Despite the availability of effective vaccines and antiviral therapy over the past two to three decades, chronic hepatitis B virus (HBV) infection remains a major global health threat as a leading cause of cirrhosis and liver cancer.
M. Moini, S. Fung
semanticscholar +1 more source
Objective Hepatitis B virus (HBV)-specific T cells are main effector cells in the control of HBV infection and hepatitis B surface antigen (HBsAg) is suggested to be a critical factor in the impaired immune response, a hallmark of chronic HBV infection ...
E. Aliabadi+9 more
semanticscholar +1 more source
Hepatitis B infection among hemodialysis patients in Al-Jazirah State: a seroepidemiological survey
Hemodialysis patients are more susceptible to HBV infection because they have low immunity and can be inflicted through an improperly sterilized machine or through a tainted blood transfusion.
Moglad Ehssan H. O.+2 more
doaj +1 more source
How does the immunogenicity of hepatitis B vaccine change over the years in childhood?
Hepatitis B is the leading cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma worldwide. The incidence of HBV infection has significantly decreased with hepatitis B vaccination. Hepatitis B vaccine is administered to children at 0, 1 and
Gulsum Iclal Bayhan+3 more
doaj +1 more source
Chronic hepatitis B (CHB) infection functional cure is defined as sustained loss of HBsAg and several therapeutic strategies are in clinical development designed to pharmacologically reduce serum HBsAg, break immune tolerance, and increase functional ...
Jin Hyang Kim+11 more
semanticscholar +1 more source
BACKGROUND & AIMS Seroclearance of hepatitis B surface antigen (HBsAg) is a marker for clearance of chronic hepatitis B virus (HBV) infection, but reported annual incidence rates of HBsAg seroclearance vary.
Y. Yeo+38 more
semanticscholar +1 more source
Hepatitis D virus (HDV) requires hepatitis B surface antigen (HBsAg) for its assembly and release. Current HBV treatments are only marginally effective against HDV because they fail to inhibit HBsAg production/secretion.
L. Shekhtman+12 more
semanticscholar +1 more source
Significance We detected cfDNA somatic mutations in combination with protein markers to efficiently identify early stage HCC from asymptomatic HBsAg-seropositive individuals in a community population.
C. Qu+35 more
semanticscholar +1 more source
Introduction. The achievement of the goal of the World Health Organization to eliminate viral hepatitis B by 2030 seems to be problematic partly due to the presence of escape mutants of its etiological agent, hepatitis B virus (HBV) (iHepadnaviridae ...
M. V. Konopleva+7 more
doaj +1 more source
Breakdown of adaptive immunotolerance induces hepatocellular carcinoma in HBsAg-tg mice
Hepatitis B virus (HBV) can induce chronic inflammation, cirrhosis, and eventually hepatocellular carcinoma (HCC). Despite evidence suggesting a link between adaptive immunity and HBV-related diseases in humans, the immunopathogenic mechanisms involved ...
Lu Zong+8 more
semanticscholar +1 more source